Insmed was one of the 5 biotechnology stocks recommended to buy now .This is a strong week for Insmed Incorporated Insmed. The company’s rating climbs to B from the previous week’s C. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. Investors seem to agree with the upgraded status of the stock and have pushed the stock up 5.4% over the past month.
investor place has it all there from December 25th
Best regards to everyone
Our wildest dream have come true i couldnt imagine $17.00 closing price for 2013.
I know God willing our dreams will be even closer to reality in 2014 .
Many thanks to Mr; Lewis for his superior leadership and as we all know he is the reason for all of Insmed's success so far and may he be successful to the end for the sake of the patients.
Best regards to all true longs of Insmed.
I want to wish everyone on this board a happy, healthy and wealthy new year.
On Tuesday Insmed inc.'s Stock advanced to close the day at $16.31,which is 0.74% higher than the previous day closing price of $16.19.The company's share fluctuated between $15.90 and $16.65 during the trading session.A total of 0.37 million shares were tarded which is below the average volume of 0.59 million.The company's shares have have gained 8.3% in the last one month and 7.73 % in the previous 3 month, outperforming the S 500 which has gained 1.81% and 7.04% during the respective periods.FurthermoreInsmedInc's stock is trading above it's 50 day and 200 day moving averages of $15.05 and $11.78,respectively.